| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EBS | Employee Stock Options (Right to Buy) | Award | $0 | +250,000 | +24% | $0.000000 | 1,282,500 | 12 Mar 2025 | Common Stock | 250,000 | $2.33 | Direct | F1 |
| transaction | EBS | Employee Stock Options (Right to Buy) | Award | $0 | +250,000 | +19% | $0.000000 | 1,532,500 | 12 Mar 2025 | Common Stock | 250,000 | $2.33 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | Consists of an award of performance stock options granted under the company's Inducement Plan. These performance stock options vested in one annual installment on the day prior to the first anniversary of the date of grant based on the achievement of the $5 and $10 stock price performance hurdles as described in Mr. Papa's executive employment agreement dated February 19, 2024 (the "Papa Employment Agreement") and as certified by the company's Compensation Committee on February 12, 2025. Pursuant to the award, there remains 250,000 unvested performance stock options that are subject to a $15 stock price performance hurdle as described in the Papa Employment Agreement. Each performance stock option represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc. at the exercise price. |